Boehringer Shoots For Schizophrenia With PDE9 Inhibitor, Ends Alzheimer's R&D

 
• By Lucie Ellis-Taitt
  
Fork in the road
Boehringer takes a different path with pipeline drug after Alzheimer's Phase II miss • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D